Technical Analysis for ADAP - Adaptimmune Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 20 DMA | Bearish | 3.64% | |
| Earnings Movers | Other | 3.64% | |
| Wide Bands | Range Expansion | 3.64% | |
| 20 DMA Support | Bullish | -0.87% | |
| Earnings Movers | Other | -0.87% | |
| Weak + Overbought | Other | -0.87% | |
| Wide Bands | Range Expansion | -0.87% | |
| Gapped Up | Strength | -0.87% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/06/2024
Adaptimmune Therapeutics plc Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Acid Immunotherapy Cancer Treatment Cancer Immunotherapy Virotherapy Non Small Cell Lung Cancer Melanoma Ovarian Cancer Small Cell Lung Cancer Multiple Myeloma Sarcoma Peptides Hematological Malignancies Oncolytics Biotech Adoptive Cell Transfer Immunotherapy Products Tumors Of The Hematopoietic And Lymphoid Tissues Amino Acids Cancer Immunotherapy Product Synovial Sarcoma Breast And Lung Cancer Esophageal Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.05 |
| 52 Week Low | 0.42 |
| Average Volume | 1,521,429 |
| 200-Day Moving Average | 0.91 |
| 50-Day Moving Average | 1.33 |
| 20-Day Moving Average | 1.10 |
| 10-Day Moving Average | 1.15 |
| Average True Range | 0.11 |
| RSI (14) | 46.52 |
| ADX | 15.47 |
| +DI | 16.52 |
| -DI | 24.25 |
| Chandelier Exit (Long, 3 ATRs) | 1.07 |
| Chandelier Exit (Short, 3 ATRs) | 1.21 |
| Upper Bollinger Bands | 1.29 |
| Lower Bollinger Band | 0.92 |
| Percent B (%b) | 0.6 |
| BandWidth | 33.48 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0165 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.32 | ||||
| Resistance 3 (R3) | 1.30 | 1.22 | 1.29 | ||
| Resistance 2 (R2) | 1.22 | 1.17 | 1.23 | 1.28 | |
| Resistance 1 (R1) | 1.18 | 1.15 | 1.20 | 1.20 | 1.27 |
| Pivot Point | 1.10 | 1.10 | 1.11 | 1.11 | 1.10 |
| Support 1 (S1) | 1.06 | 1.05 | 1.08 | 1.08 | 1.01 |
| Support 2 (S2) | 0.98 | 1.03 | 0.99 | 1.00 | |
| Support 3 (S3) | 0.94 | 0.98 | 0.99 | ||
| Support 4 (S4) | 0.96 |
